Intelligent Bio Solutions Stock (NASDAQ:INBS)


RevenueFinancialsChart

Previous Close

$1.47

52W Range

$1.00 - $11.70

50D Avg

$1.55

200D Avg

$2.15

Market Cap

$6.07M

Avg Vol (3M)

$149.06K

Beta

4.72

Div Yield

-

INBS Company Profile


Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

50

IPO Date

Dec 23, 2020

Website

INBS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 24Jun 23
Other Sales$623.48K$196.71K

Fiscal year ends in Jun 24 | Currency in USD

INBS Financial Summary


Jun 24Jun 23Jun 22
Revenue$3.11M$1.26M-
Operating Income$-10.28M$-12.60M$-8.34M
Net Income$-10.16M$-10.63M$-8.31M
EBITDA$-11.48M$-7.46M$-8.32M
Basic EPS$-6.38$-10.58$-11.33
Diluted EPS$-6.38$-10.58$-11.33

Fiscal year ends in Jun 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 23Nov 11, 22 | 11:22 PM
Q4 22Sep 01, 22 | 6:40 PM
Q3 22May 14, 22 | 11:28 PM